TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4<sup>+</sup>T cells in Preeclampsia Patients

Kamrani, Amin; Soltani‐Zangbar, Mohammad Sadegh; Shiri, Sadaf; Yousefzadeh, Yousef; Pourakbari, Ramin; Aghebati‐Maleki, Leili; Mehdizadeh, Amir; Danaii, Shahla; Jadidi‐Niaragh, Farhad; Yousefi, Bahman; Kafil, Hossein Samadi; Hojjat‐Farsangi, Mohammad; Motavalli, Roza; Zolfaghari, Mohammad Ali; Haji-Fatahaliha, Mostafa; Mahmoodpoor, Ata; Heris, Javad Ahmadian; Emdadi, Asma; Yousefi, Mehdi

doi:10.1080/08820139.2021.1904976

Cited by 16 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…100 Recent studies have shown that the proportion of Tigit + CD4 + , Tigit + CD8 + T cells in the peripheral blood of PE patients is significantly decreased compared to controls. 99,101 Decreased CD226 expression and increased CD112 and CD155 surface expression were found in all T cell, NK cell, and monocyte subpopulations in women diagnosed with PE compared to the healthy group. 99 Blocking Tigit (PxxP, two in CD28 and one in CTLA-4).…”

Section: Tigit Signaling In Normal Pregnancy and Pregnancy Complicationsmentioning

confidence: 99%

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Zhao

Muyayalo

Luo

et al. 2022

Immunological Reviews

View full text Add to dashboard Cite

Successful pregnancy is a unique situation requires the maternal immune system to recognize and tolerate a semi‐identical fetus and allow normal invasion of trophoblast cells. Although efforts have been made, the deep mechanisms of the maternal‐fetal crosstalk have not yet been fully deciphered. Immune checkpoint molecules (ICMs) are a group of negative modulators of the immune response that avoid immune damage. They have been extensively studied in the fields of oncology and transplantation, while the latest evidence suggests that they are closely associated with pregnancy outcomes via multiple inhibitory mechanisms. Although studies have mostly demonstrated the regulatory role of the well‐known PD‐1, CTLA‐4 at the maternal‐fetal interface, what is unique about the newly discovered multiple ICMs remains a mystery. Here, we review the latest knowledge on ICMs, focusing on the first generation of checkpoints (PD‐1, CTLA‐4) and the next generation (Tim‐3, Tigit, Lag‐3, VISTA) highlighting their immunoregulatory roles in maternal‐fetal tolerance and decidual vascular remodeling, and their involvement in pathological pregnancies. The content covers three aspects: the characteristics they possess, the dynamic expression profile of their expression at the maternal‐fetal interface, and their involvement in pathological pregnancy. In immunotherapy strategies for pregnancy complications, upregulation of immune checkpoints may play a role. Meanwhile, the impact on pregnancy outcomes when using ICMs in clinical cancer treatment during pregnancy is a topic worth exploring. These may serve as a guide for future basic research and clinical applications of maternal‐fetal immunity.

show abstract

Section: Tigit Signaling In Normal Pregnancy and Pregnancy Complicationsmentioning

confidence: 99%

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Zhao

Muyayalo

Luo

et al. 2022

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…A study about unexplained recurrent miscarriage patients and normal pregnancy showed that an increased expression of TIGIT in the decidual γδT cells significantly plays essential roles in maintaining pregnancy, 126,127 which was also confirmed in a study of patients with pre-eclampsia. 128 Fu et al detected the expression of TIGIT in decidual immune cells at the maternal-fetal interface. Then by generating recombinant TIGIT-Fc fusion proteins, they confirmed that treatment with TIGIT-Fc of human decidual immune cells could increase IL-10 production, leading the decidual CD4 + T cells to a Th2 phenotype, suggesting that TIGIT-Fc fusion protein has therapeutic potential in pregnancy failure.…”

Section: Human Pregnancy and Pregnancyrelated Diseasesmentioning

confidence: 99%

The landscape of TIGIT target and clinical application in diseases

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint blockade has dramatically altered the concept of cancer therapeutics over the past few years. Beyond the existing classical pathways, novel immune checkpoints, such as T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif (ITIM) structural domain (TIGIT), have also emerged in recent years and have promising therapeutic potential. Recent researches have provided ample evidence that TIGIT is extensively involved in various cancerous and noncancerous diseases such as chronic inflammation, autoimmune diseases, abnormal pregnancy status, and most recently coronavirus disease 2019. In contrast to the programmed cell death receptor 1 pathway which primarily affects T‐cell function, targeting TIGIT pathway regulates multiple types of immunocytes but has fewer immune‐related adverse events. Owing to its unique advantages and extensive involvement in diseases, extensive clinical trials blockade TIGIT or combine it with other targets are ongoing, and numerous phase II clinical trials have already seen promising results. In this review, we summarized the existing research on TIGIT in various diseases and discussed the perspective and challenges related to targeting this molecular for therapy, with an attempt to provide directions for subsequent studies.

show abstract

“…Peripheral and decidual Treg cells increase during normal pregnancy. 10,11 Tregs exert suppressive functions through different mechanisms, including the modulation of antigen presentation, the cytolysis of target cells, and the secretion of inhibiting cytokines. 12,13 Treg cells prevent the operation and proliferation of Th17 and Th1 cells via different mechanisms, including programmed cell death protein 1 (PD-1) and the Ca + influx-clapin-caspase 1 pathway.…”

Section: Lymphoc Y Te S and Preg Nan C Ymentioning

confidence: 99%

“…Additionally, Treg cells are the main factors for immunological tolerance, the acceptance of the fetus by the mother's immune system, and embryo implantation. Peripheral and decidual Treg cells increase during normal pregnancy 10,11 . Tregs exert suppressive functions through different mechanisms, including the modulation of antigen presentation, the cytolysis of target cells, and the secretion of inhibiting cytokines 12,13 .…”

Section: Lymphocytes and Pregnancymentioning

confidence: 99%

T lymphocytes and preeclampsia: The potential role of T‐cell subsets and related MicroRNAs in the pathogenesis of preeclampsia

Zolfaghari

ArefNezhad

Parhizkar

et al. 2021

American J Rep Immunol

Self Cite

View full text Add to dashboard Cite

Innate and adaptive immune systems have a crucial role in initiating and progressing some pregnancy disorders such as preeclampsia (PE), which is one of the pregnancy‐specific disorders that could result in neonatal and maternal morbidity and mortality. The dysregulation of the spiral artery and inadequate trophoblast invasion lead to PE symptoms through producing various inflammatory cytokines and anti‐angiogenic factors from the placenta. T lymphocytes play a special role in the epithelium and stroma of the human endometrium. CD4+ T helper (Th) cells, Th1/Th2, and Th17/T regulatory (Treg) balance mainly contribute to the establishment of a pregnancy‐favorable environment. This review examined the dysregulation of some cytokines produced from T cells, the dysregulation of the transcription factors of Th cells, the expression of chemokine receptors on T cells, as well as the effects of some factors including vitamin D on the activity of T cells, and finally, the dysregulation of various miRNAs related to T cells, which could cause PE.

show abstract

TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4⁺T cells in Preeclampsia Patients

Cited by 16 publications

References 43 publications

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

The landscape of TIGIT target and clinical application in diseases

T lymphocytes and preeclampsia: The potential role of T‐cell subsets and related MicroRNAs in the pathogenesis of preeclampsia

Contact Info

Product

Resources

About

TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4+T cells in Preeclampsia Patients

Cited by 16 publications

References 43 publications

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

The landscape of TIGIT target and clinical application in diseases

T lymphocytes and preeclampsia: The potential role of T‐cell subsets and related MicroRNAs in the pathogenesis of preeclampsia

Contact Info

Product

Resources

About

TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4⁺T cells in Preeclampsia Patients